Regencell Bioscience Holdings Stock
Regencell Bioscience Holdings Limited
Company data
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- Hong Kong SAR China
- CEO
- Yat-Gai Au
- Employees
- 10
- Market cap
- $4.8 B
- IPO
- 16/07/2021
Regencell Bioscience Holdings Limited is a biotechnology firm operating within the healthcare sector, specializing in Traditional Chinese Medicine (TCM). The company's core activities revolve around the research, development, and market introduction of TCM solutions specifically designed to address neurocognitive…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Regencell Bioscience Holdings stock: price history
1D
+0.7%
1W
+30.5%
1M
+68.8%
6M
-66.6%
YTD
-54.3%
1Y
-46.6%
2Y
+7,188.3%
5Y
+1,855.0%
10Y
–
Next earnings date
Next earnings date
28/10/2026 (in 11 days)
Volatility around earnings
~22% weaker price swings than usual
Regencell Bioscience Holdings stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 18/08/2026.
Ask the agents about Regencell Bioscience Holdings
Analyst assessment of Regencell Bioscience Holdings
0
STRONG BUY
0
BUY
4
HOLD
0
SELL
0
STRONG SELL
4
TOTAL · Hold
As of: 02/01/2018
Regencell Bioscience Holdings stock metrics
P/E
-406.36
P/B
355.38
EV/EBITDA
-418.88
RETURN ON EQUITY
-47.8%
NET MARGIN
0.0%
DEBT/EQUITY
0.02
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
3.5%
FLOAT SHARES
17,296,433
AVG. DAILY VOLUME (30D)
274,959
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: +0.7%
Forums (Reddit)
Institutional holders
Dividends & Stock splits
Dividends
Stock splits
Comparable stocks
Frequently asked questions about Regencell Bioscience Holdings stock
What does Regencell Bioscience Holdings do?
Regencell Bioscience Holdings Limited is a company in the Healthcare sector, Drug Manufacturers - Specialty & Generic industry, headquartered in Hong Kong SAR China.
The CEO is Yat-Gai Au, the company employs around 10 people.
The IPO was on 16/07/2021; the stock trades on NASDAQ under the ticker RGC.
What do analysts say about Regencell Bioscience Holdings stock?
4 analysts rate the stock, the consensus is Hold (as of 02/01/2018).
This is an external assessment, not a statement by Market Jury.
When does Regencell Bioscience Holdings report next?
The next earnings date is 28/10/2026.
Around past earnings, price swings were roughly -22% stronger than usual.
Does Regencell Bioscience Holdings pay a dividend?
Yes. The last dividend was US$8.36 per share, ex-date 15/02/2018, paid on 26/02/2018.
The dividend yield is 0.0% (as of 30/06/2026).
Which stocks are comparable to Regencell Bioscience Holdings?
Comparable stocks include Merck, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries, Zoetis, Sandoz Group, Viatris, Lantheus Holdings and Amneal Pharmaceuticals.
How can I get Regencell Bioscience Holdings stock analyzed?
Clicking "Analyze stock" lets five strategies assess Regencell Bioscience Holdings against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.